Los Angeles Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Los Angeles Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24,947	Closed	-$297K	–	1494
2022 Q1	$297K	Sell	24,947 -822	-3%	-$14.7K	﹤0.01%	1243
2021 Q4	$840K	Sell	25,769 -125	-0.5%	-$5.06K	﹤0.01%	786
2021 Q3	$1.16M	Sell	25,894 -1,257	-5%	-$61.4K	0.01%	710
2021 Q2	$1.48M	Buy	27,151 +18,113	+200%	+$1.07M	0.01%	684
2021 Q1	$676K	Sell	9,038 -2,495	-22%	-$259K	﹤0.01%	1083
2020 Q4	$1.25M	Buy	11,533 +901	+8%	+$82.2K	0.01%	838
2020 Q3	$940K	Buy	10,632 +2,321	+28%	+$264K	﹤0.01%	846
2020 Q2	$886K	Buy	8,311 +3,627	+77%	+$326K	﹤0.01%	894
2020 Q1	$278K	Buy	4,684 +3,564	+318%	+$242K	﹤0.01%	1079
2019 Q4	$77K	Buy	+1,120	New	+$67.9K	﹤0.01%	1243
2019 Q3	–	Sell	-4,037	Closed	-$374K	–	1387
2019 Q2	$374K	Sell	4,037 -1	-0%	-$70	﹤0.01%	1118
2019 Q1	$369K	Buy	4,038 +310	+8%	+$21.6K	﹤0.01%	1152
2018 Q4	$208K	Sell	3,728 -35	-0.9%	-$2.66K	﹤0.01%	1198
2018 Q3	$448K	Sell	3,763 -2,226	-37%	-$258K	﹤0.01%	1126
2018 Q2	$611K	Buy	+5,989	New	+$742K	﹤0.01%	1076

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Los Angeles Capital Management's SYRS Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 24,947 shares — an estimated $297K sold.

Los Angeles Capital Management first reported a position in SYRS in Q2 2018 and held it in 15 quarters. The position peaked at $1.48M in Q2 2021. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

Los Angeles Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Los Angeles Capital Management sold 24,947 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $297K.
Los Angeles Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 15 quarters.
Los Angeles Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.48M in Q2 2021.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.